![](/img/cover-not-exists.png)
7027 Interim results of a phase II trial of oxaliplatin and pemetrexed as 2nd/3rd line therapy in castration resistant prostate cancer (CRPC)
Dorff, T.B., Groshen, S., Tsao-Wei, D.D., Goldkorn, A., Korn, C., Quinn, D.I., Pinski, J.Volume:
7
Language:
english
Journal:
European Journal of Cancer Supplements
DOI:
10.1016/S1359-6349(09)71405-3
Date:
September, 2009
File:
PDF, 71 KB
english, 2009